Cervical cancer screening, what the guidelines actually say

Cervical cancer screening is one of the clearer public-health success stories in this list, and it is also, right now, mid-update: a change is on the table that has not yet been finalized. This page describes the guideline that is currently in force and is explicit about the one that might replace part of it.

What this screening is and what it looks for

Cervical cancer screening looks for either abnormal cervical cells (cytology, commonly called a Pap test) or high-risk strains of human papillomavirus (hrHPV testing), the virus responsible for nearly all cervical cancer. Screening does not find cancer directly so much as it finds precancerous changes early enough that they can be monitored or treated before they progress, which is a large part of why cervical cancer death rates have fallen so much since the Pap test became routine.

The USPSTF frames its current recommendation around “individuals with a cervix,” and its operative recommendation sentences use “women,” so both should be understood to apply: the guideline is about anyone with a cervix in the eligible age range, regardless of sexual history.

Who and when, per the USPSTF

The 2018 recommendation, still the current final statement, gives a single Grade A across ages 21 to 65 but splits the accepted method by age:

• Ages 21 to 29: cytology alone every 3 years. This is the only strategy the Task Force recommends in this age band.
• Ages 30 to 65: three accepted strategies, all Grade A. Cytology alone every 3 years, high-risk HPV testing alone every 5 years, or cytology combined with hrHPV testing (cotesting) every 5 years. The Task Force does not rank these against each other; any of the three satisfies the recommendation.
• Younger than 21, or older than 65 with adequate prior screening and no other risk factor: Grade D, meaning the Task Force recommends against routine screening in these groups.

This recommendation does not cover everyone. It excludes people who have had a total hysterectomy with the cervix removed for a benign condition and no history of a high-grade precancerous lesion, and it does not apply to people with a compromised immune system (including HIV), a history of in-utero DES exposure, or a prior high-grade cervical lesion or cervical cancer, all of whom need a different, individualized screening approach that this statement does not define.

These age bands and test choices describe guideline eligibility and the evidence behind each strategy, not an instruction that any particular person should be screened on a particular date or follow a particular testing approach. When and whether to screen, and which of the accepted methods fits your situation, is a conversation for a clinician who knows your history and risk factors.

The evidence and its grade

The USPSTF’s Grade A here reflects high certainty of a substantial net benefit, the strongest rating the Task Force issues, built on decades of population-level evidence that regular screening and treatment of precancerous lesions prevents cervical cancer deaths. The 3-strategy structure for ages 30 to 65 reflects a genuinely open scientific question rather than administrative flexibility: cytology, hrHPV testing, and cotesting have different sensitivity and false-positive tradeoffs, and the evidence has not shown one to be clearly superior once each is used on its own recommended interval.

Where the guidance differs

The 2018 statement is still the operative final recommendation, but it is not the only thing in motion. In December 2024, the USPSTF opened a draft recommendation proposing that primary hrHPV testing, collected either by a clinician or by the patient themselves during a clinical visit, become the preferred strategy for ages 30 to 65, with cytology-alone and cotesting continuing as alternatives. As of this writing, that draft has not been finalized into a new recommendation statement, so it should not be described as current USPSTF guidance. Separately, and through a different process entirely, the Health Resources and Services Administration finalized an update to its Women’s Preventive Services Guidelines in January 2026 (effective for insurance plan years starting January 1, 2027) that requires coverage of patient-collected hrHPV testing; that is an insurance-coverage mandate from a different federal body, not a finalized USPSTF clinical recommendation, and the two should not be conflated. On the technology itself, the FDA approved the first HPV tests for self-collection in a health care setting in May 2024, so the underlying tools exist and are authorized for use even while the guideline language around them is still being finalized.

Questions to ask your clinician

Framed as questions to bring to a visit, not as steps to take on your own:

• Given my age, which of the accepted strategies, cytology, hrHPV testing, or cotesting, fits my situation, and what are the tradeoffs between them?
• I have had a hysterectomy or another gynecologic procedure; does the current recommendation still apply to me, or do I need a different plan?
• I have a risk factor such as HIV, a prior high-grade result, or in-utero DES exposure; how does my screening plan differ from the average-risk guideline described here?
• I have heard about self-collected HPV testing; is that available to me now, and how does its evidence base compare to the currently recommended methods?
• If my result comes back abnormal or positive, what is the next step, and on what timeline should it happen?

You can compare this profile against the full Guideline Tracker, read the sibling profiles for breast cancer screening and colorectal cancer screening, or see how everyday choices fit alongside screening in the big levers.